Investigational drug · Phase 2
NX210c
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "NX210c"
First trial start
2024
Oct 25, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NX210c", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "NX210c" as an intervention, largest first.
- ALS Phase II Study of NX210cCompleted
Axoltis PharmaIndustry
NCT06365216 · 83 participants · Start Oct 25, 2024 · Primary completion Dec 29, 2025
Drug: NX210c; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: Brest, France; Caen, France; Marseille, France · 16 sites in all
- MAD Study of NX210cCompleted
Axoltis PharmaIndustry
NCT05827653 · 29 participants · Start Dec 5, 2022 · Primary completion Apr 29, 2023
Drug: NX210c; Placebo · For: Healthy Elderly
Sites: Leiden, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Administration of a Novel Peptide Derived From Thrombospondin Repeat Sequences Enhances Recovery after Cervical Spinal Cord Injury.
Punjani N, Lemarchant S, Altamentova S, et al. · J Neurotrauma 2026
- NX210c Demonstrates Therapeutic Potential to Restore Blood-Brain Barrier in a QSP Model of Relapsing-Remitting Multiple Sclerosis.
Russo G, Sips F, Catozzi S, et al. · Int J Mol Sci 2026
- Smart zwitterionic biodegradable hydrogel for sustained peptide delivery: Application to the neurotherapeutic peptide NX210c.
Rosson E, Thomas E, Sidi-Boumedine J, et al. · Biomater Adv 2026
- Safety, Tolerability and Pharmacokinetic-Pharmacodynamic Relationship of NX210c Peptide in Healthy Elderly Volunteers: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study.
Janus A, Dumas D, Le Douce J, et al. · Neurol Ther 2025
- NX210c drug candidate peptide strengthens mouse and human blood-brain barriers.
Greene C, Rebergue N, Fewell G, et al. · Fluids Barriers CNS 2024
- NX210c Peptide Promotes Glutamatergic Receptor-Mediated Synaptic Transmission and Signaling in the Mouse Central Nervous System.
Lemarchant S, Sourioux M, Le Douce J, et al. · Int J Mol Sci 2022
Also in development for Amyotrophic Lateral Sclerosis
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.